I-Mab Q1 Loss Narrows; Givastomig Combination Data Selected For Presentation At ESMO GI
15/5 13:26
(RTTNews) - I-Mab (IMAB), a biotech company, Thursday reported net loss from continuing operations of $3.15 million or $0.02 per share for the first quarter, lower than $9.42 million or $0.05 per share loss in the same quarter a year ago....